Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers [Phase 1]

View source ↗

Summary

The study evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2256294 in healthy volunteers and in adult male moderately obese smokers, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK2256294 (GSK2256294)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED